Eya3 promotes breast tumor–associated immune suppression via threonine phosphatase–mediated PD-L1 upregulation

Rebecca L. Vartuli, Hengbo Zhou, Lingdi Zhang, Rani K. Powers, Jared Klarquist, Pratyaydipta Rudra, Melanie Y. Vincent, Debashis Ghosh, James C. Costello, Ross M. Kedl, Jill E. Slansky, Rui Zhao (+1 others)
2018 Journal of Clinical Investigation  
at a static time point, we tested whether there was a significant difference between SCR versus Eya3 KD2 and KD3. This was done using an ANOVA by comparing the effect of SCR against the average effect of KD2 and KD3 (done using sum contrasts in R) and the corresponding P value was reported. All graphs were created using GraphPad Prism software. If exact P values were not stated, reported P values are as follows: *P < 0.05, **P < 0.01, ***P < 0.001. Study approval. All animal studies were
more » ... ed according to protocol B-57716(04)1E reviewed and approved by the Institutional Animal Care and Use Committee at the University of Colorado Anschutz Medical Campus.
doi:10.1172/jci96784 pmid:29757193 fatcat:7asjdqc3lfcu7f6qxd7xvigjha